[go: up one dir, main page]

MX2011008000A - Analogos de ciclosporina para la prevención o tratamiento de la infeccion de hepatitis c. - Google Patents

Analogos de ciclosporina para la prevención o tratamiento de la infeccion de hepatitis c.

Info

Publication number
MX2011008000A
MX2011008000A MX2011008000A MX2011008000A MX2011008000A MX 2011008000 A MX2011008000 A MX 2011008000A MX 2011008000 A MX2011008000 A MX 2011008000A MX 2011008000 A MX2011008000 A MX 2011008000A MX 2011008000 A MX2011008000 A MX 2011008000A
Authority
MX
Mexico
Prior art keywords
infection
preventing
treating hepatitis
cyclosporin analogues
compounds
Prior art date
Application number
MX2011008000A
Other languages
English (en)
Inventor
Yat Sun Or
Guoqiang Wang
Jiang Long
Xuri Gao
Original Assignee
Enanta Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enanta Pharm Inc filed Critical Enanta Pharm Inc
Publication of MX2011008000A publication Critical patent/MX2011008000A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D259/00Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • C07K7/645Cyclosporins; Related peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a análogos de ciclosporina que tienen actividad antiviral contra el VHC, y útiles en el tratamiento de VHC. Más particularmente, la invención se refiere a nuevos compuestos análogos de ciclosporina, las composiciones que contienen dichos compuestos y los métodos para usar los mismos, así como los procesos para hacer dichos compuestos.
MX2011008000A 2009-01-30 2010-01-30 Analogos de ciclosporina para la prevención o tratamiento de la infeccion de hepatitis c. MX2011008000A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14858309P 2009-01-30 2009-01-30
PCT/US2010/022675 WO2010088573A1 (en) 2009-01-30 2010-01-30 Cyclosporin analogues for preventing or treating hepatitis c infection

Publications (1)

Publication Number Publication Date
MX2011008000A true MX2011008000A (es) 2011-09-15

Family

ID=42396050

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008000A MX2011008000A (es) 2009-01-30 2010-01-30 Analogos de ciclosporina para la prevención o tratamiento de la infeccion de hepatitis c.

Country Status (14)

Country Link
US (3) US8367618B2 (es)
EP (1) EP2391376A4 (es)
JP (1) JP5406943B2 (es)
KR (2) KR20110111321A (es)
CN (1) CN102365094A (es)
AU (1) AU2010208071C1 (es)
BR (1) BRPI1007476A2 (es)
CA (1) CA2751210C (es)
IL (1) IL214278A0 (es)
MX (1) MX2011008000A (es)
NZ (1) NZ594755A (es)
RU (1) RU2492181C2 (es)
SG (1) SG173180A1 (es)
WO (1) WO2010088573A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010088573A1 (en) * 2009-01-30 2010-08-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis c infection
US8481483B2 (en) * 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) * 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) * 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8685917B2 (en) * 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
JP2013516424A (ja) * 2009-12-30 2013-05-13 サイネクシス,インコーポレーテッド シクロスポリン類似体
US8623814B2 (en) * 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
CN103153329A (zh) 2010-07-16 2013-06-12 美国科技环球有限公司 新颖的环孢霉素a衍生物在病毒感染的治疗和预防中的应用
WO2012021796A2 (en) * 2010-08-12 2012-02-16 S&T Global, Inc. Novel cyclosporin derivatives for the treatment and prevention of a viral infection
AU2011336266B2 (en) * 2010-12-03 2017-04-06 S&T Global Inc. Novel cyclosporin derivatives for the treatment and prevention of a viral infection
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
PL2651965T3 (pl) 2010-12-15 2019-04-30 Contravir Pharmaceuticals Inc Cząsteczki analogów cyklosporyny modyfikowane w aminokwasach 1 i 3
US9428845B1 (en) 2010-12-28 2016-08-30 Warp Drive Bio, Inc. Identifying new therapeutic agents
AR090964A1 (es) * 2012-05-09 2014-12-17 Novartis Ag Proceso para la elaboracion de undecapeptidos ciclicos
AU2013267435B2 (en) 2012-06-01 2017-11-09 Allergan, Inc. Cyclosporin A analogs
CN104603146B (zh) * 2012-09-29 2018-01-02 诺华股份有限公司 环肽类化合物及其作为药物的用途
WO2014085623A1 (en) * 2012-11-28 2014-06-05 Enanta Pharmaceuticals, Inc. Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues
WO2015031381A1 (en) * 2013-08-26 2015-03-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis c
JP6413455B2 (ja) * 2014-08-07 2018-10-31 日本電気株式会社 給湯機制御装置、給湯機制御システム、給湯機制御方法およびプログラム
GB201414806D0 (en) 2014-08-20 2014-10-01 Ucl Business Plc Cyclosporin conjugates
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
CN105693820A (zh) * 2014-11-27 2016-06-22 武汉药明康德新药开发有限公司 一种降解环孢菌素a的方法
WO2016112321A1 (en) 2015-01-08 2016-07-14 Allergan, Inc. Cyclosporin derivatives wherein the mebmt sidechain has been cyclized
WO2016112295A1 (en) 2015-01-09 2016-07-14 Warp Drive Bio, Inc. Compounds that participate in cooperative binding and uses thereof
TW201629069A (zh) 2015-01-09 2016-08-16 霍普驅動生物科技股份有限公司 參與協同結合之化合物及其用途
EP3355930A4 (en) 2015-10-01 2019-03-06 Warp Drive Bio, Inc. METHOD AND REAGENTS FOR THE ANALYSIS OF PROTEIN-PROTEIN INTERFACES
EP4085933A3 (en) 2016-04-12 2023-01-11 Ginkgo Bioworks, Inc. Compositions and methods for the production of compounds
WO2018081592A2 (en) 2016-10-28 2018-05-03 Warp Drive Bio, Inc. Compositions and methods for the production of compounds
CA3159561A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
AU2020379731A1 (en) 2019-11-04 2022-05-05 Revolution Medicines, Inc. Ras inhibitors
KR20220158761A (ko) * 2020-03-26 2022-12-01 파사이트 메디컬 테크놀로지 (상하이) 컴퍼니 리미티드 사이클로스포린 유도체의 제조
PE20231207A1 (es) 2020-09-15 2023-08-17 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer
PE20240089A1 (es) 2021-05-05 2024-01-16 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cancer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH614931A5 (es) 1975-11-04 1979-12-28 Sandoz Ag
DE2819094A1 (de) 1977-05-10 1978-11-23 Sandoz Ag Cyclosporin-derivate, ihre verwendung und herstellung
SE448386B (sv) 1978-10-18 1987-02-16 Sandoz Ag Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem
IE54936B1 (en) 1980-02-14 1990-03-28 Sandoz Ltd A method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
US4396542A (en) 1980-02-14 1983-08-02 Sandoz Ltd. Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
EP0056782B1 (en) 1981-01-09 1984-08-01 Sandoz Ag Novel cyclosporins
ATE92501T1 (de) 1984-10-04 1993-08-15 Sandoz Ag Monoklonale antikoerper gegen zyklosporine.
EP0194972B1 (en) 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
US5239057A (en) 1987-03-27 1993-08-24 Abbott Laboratories Fluorescence polarization assay for cyclosporin a and metabolites and related immunogens and antibodies
US4798823A (en) 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
DE3884470T2 (de) 1987-06-17 1994-03-10 Sandoz Ag Cyclosporine und deren Benutzung als Arzneimittel.
GB2206119B (en) 1987-06-22 1990-10-31 Merck & Co Inc A new cyclosporin derivative with modified "8-amino acid"
GB8717300D0 (en) 1987-07-22 1987-08-26 Nat Res Dev Cyclosporins
GB8717299D0 (en) 1987-07-22 1987-08-26 Nat Res Dev Peptides
GB2207678A (en) 1987-08-03 1989-02-08 Merck & Co Inc Novel immunosuppressive fluorinated cyclosporin analogs
US5604092A (en) * 1988-12-05 1997-02-18 The Trustees Of Columbia University In The City Of New York Method for the detection of HIV-1 using a cyclosporine-specific monoclonal antibody that reacts with the P24 Gag protein
US5284826A (en) 1989-07-24 1994-02-08 Sandoz Ltd. 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins
FR2762843B1 (fr) 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
DE69840586D1 (de) 1997-10-08 2009-04-02 Isotechnika Inc Deuterierte Cyclosporin-analoga und ihre Verwendung als immunmodulierende Agenzien
DE69928938T2 (de) * 1998-07-01 2006-08-17 Debiopharm S.A. Neues cyclosporin mit verbesserter wirkung
US6784156B2 (en) 2001-03-05 2004-08-31 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of respiratory diseases
US20030087813A1 (en) 2001-10-12 2003-05-08 Or Yat Sun Cyclosporin analogs for the treatment of lung diseases
US6809077B2 (en) * 2001-10-12 2004-10-26 Enanta Pharmaceuticals, Inc. Cyclosporin analogs for the treatment of autoimmune diseases
CN100334106C (zh) 2001-10-19 2007-08-29 伊索泰克尼卡股份有限公司 环孢菌素类似物的合成
US7012065B2 (en) 2003-02-07 2006-03-14 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of immune disorders
US20040266669A1 (en) 2003-06-20 2004-12-30 Wu Frank X. H. Cyclosporin derivatives for the treatment of immune disorders
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
MX2007000503A (es) 2004-07-14 2007-03-08 Novartis Ag Uso de una combinacion de ciclosporina e interferon pegilado para el tratamiento de hepatitis c(hcv).
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
NZ554514A (en) * 2004-10-01 2010-10-29 Scynexis Inc 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
CA2580448C (en) 2004-10-01 2012-09-18 Debiopharm Sa Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin
DE602006020152D1 (de) 2005-09-30 2011-03-31 Scynexis Inc Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion
ES2557477T3 (es) * 2005-10-26 2016-01-26 Astellas Pharma Inc. Nuevos compuestos peptídicos cíclicos
EP2460800A1 (en) 2006-03-08 2012-06-06 Achillion Pharmaceuticals, Inc. Substituted aminothiazole derivatives with anti-HCV activity
US20070232532A1 (en) 2006-03-28 2007-10-04 Amr Technology, Inc. Use of cyclosporin alkene analogues for preventing or treating viral-induced disorders
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7776832B2 (en) * 2006-04-21 2010-08-17 Gem Pharmaceuticals, Llc Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
CN101687012A (zh) * 2007-05-02 2010-03-31 安斯泰来制药有限公司 新的环肽化合物
WO2008143996A1 (en) * 2007-05-18 2008-11-27 Scynexis, Inc. New chemical processes
WO2010088573A1 (en) * 2009-01-30 2010-08-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis c infection
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8429835B2 (en) * 2009-10-21 2013-04-30 Nike, Inc. Composite shoe upper and method of making same
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
CN103153329A (zh) 2010-07-16 2013-06-12 美国科技环球有限公司 新颖的环孢霉素a衍生物在病毒感染的治疗和预防中的应用
WO2012021796A2 (en) 2010-08-12 2012-02-16 S&T Global, Inc. Novel cyclosporin derivatives for the treatment and prevention of a viral infection
WO2015031381A1 (en) * 2013-08-26 2015-03-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis c

Also Published As

Publication number Publication date
AU2010208071B2 (en) 2012-11-08
CA2751210A1 (en) 2010-08-05
EP2391376A1 (en) 2011-12-07
JP2012516850A (ja) 2012-07-26
CA2751210C (en) 2015-04-21
US9156886B2 (en) 2015-10-13
EP2391376A4 (en) 2012-08-01
KR20110111321A (ko) 2011-10-10
US20160051625A1 (en) 2016-02-25
JP5406943B2 (ja) 2014-02-05
US20100196316A1 (en) 2010-08-05
CN102365094A (zh) 2012-02-29
RU2011133900A (ru) 2013-03-10
AU2010208071A1 (en) 2011-09-01
WO2010088573A1 (en) 2010-08-05
US20130183267A1 (en) 2013-07-18
SG173180A1 (en) 2011-09-29
US9603895B2 (en) 2017-03-28
AU2010208071C1 (en) 2013-06-20
BRPI1007476A2 (pt) 2016-02-16
KR20140014323A (ko) 2014-02-05
IL214278A0 (en) 2011-09-27
KR101476626B1 (ko) 2014-12-26
NZ594755A (en) 2013-12-20
RU2492181C2 (ru) 2013-09-10
US8367618B2 (en) 2013-02-05

Similar Documents

Publication Publication Date Title
MX2011008000A (es) Analogos de ciclosporina para la prevención o tratamiento de la infeccion de hepatitis c.
PH12016500320A1 (en) Cyclosporin analogues for preventing or treating hepatitis c
PH12015500289A1 (en) Anti-viral compounds
MX2011010905A (es) Compuestos antivirales.
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
MX2010008749A (es) Inhibidores del virus de la hepatitis c.
TN2012000264A1 (en) Hepatitis c virus inhibitors
TN2012000214A1 (en) Hepatitis c virus inhibitors
MX2011008045A (es) Inhibidores del virus de la hepatitis c.
MY152971A (en) Hepatitis c virus inhibitors
MX2011009644A (es) Inhibidores del virus de la hepatitis c.
PH12013500708B1 (en) Anti-viral compounds
IL196815A0 (en) Hepatitis c virus inhibitors
MX2009004556A (es) Inhibidores de la proteasa ns3 del hcv.
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
MX2013002927A (es) Inhibidores del virus de la hepatitis c.
WO2013074386A3 (en) Hcv ns3 protease inhibitors
MX2013001237A (es) Compuestos inhibidores del virus de la hepatitis c.
EA201270555A1 (ru) Комбинации ингибиторов вируса гепатита с
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
DE602008004317D1 (de) Verbindungen zur behandlung von hepatitis c
IN2014CN03113A (es)
ATE551343T1 (de) Tetracyclische verbindungen zur behandlung von hepatitis c
MX2015011193A (es) Compuestos antivirales.

Legal Events

Date Code Title Description
FG Grant or registration